Insilico Medicine reported an early lung-function improvement for ISM001-055, a drug candidate developed using generative AI, in a trial involving 71 people with idiopathic pulmonary fibrosis, a scarring lung disease. Its November 2024 announcement describes a randomized, blinded comparison with placebo over 12 weeks. At the highest dose, the lung-function measure FVC increased by an average of 98.4 mL from baseline, while the placebo group declined by 62.3 mL. These company-reported results provide an initial efficacy signal; the small, short trial does not establish durable disease reversal.
